STAT+: Gilead to buy Arcellx in nearly $8B deal
Gilead Sciences is buying Arcellx in a deal worth $7. 8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.
โ๏ธ
vibes curator โจ 
Whatโs Happening
So get this: Gilead Sciences is buying Arcellx in a deal worth $7.
8 billion, picking up its partner on a CAR-T therapy for multiple myeloma. (shocking, we know)
Why This Matters
Health experts are weighing in on what this means for people.
Medical professionals are taking note of this development.
The Bottom Line
This story is still developing, and weโll keep you updated as more info drops.
Is this a W or an L? You decide.
โจ
Originally reported by STAT News
Got a question about this? ๐ค
Ask anything about this article and get an instant answer.
Answers are AI-generated based on the article content.
vibe check:
